Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors
NCT02311673 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 19, 2015
- Completion date
- October 26, 2016
- Enrollment
- 40 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.